New Delhi

Drug major Cipla on Tuesday said its consolidated net profit increased by 48.73 per cent to Rs 1,570.51 crore for the third quarter ended December 31, 2024, riding on the back of growth across markets.

The company had reported a net profit of Rs 1,055.9 crore in the October-December period of last fiscal. Revenue from operations rose to Rs 7,072.97 crore as against Rs 6,603.81 crore in the year-ago period. 

"In Q3FY25, we delivered growth across all our various geographies, despite a supply challenge in the US," Cipla MD and Global CEO Umang Vohra said.  The company recorded a revenue growth of 8 per cent over last year with a highest-ever EBITDA margin of 28.1 per cent, driven by mix and other operational efficiencies, he added. 

"Our One-India business grew at a healthy 10 per cent year on year. Key therapies in branded prescription business continued to outpace the market growth, trade generics business growth trajectory is back on track and anchor brands of consumer health business maintained leadership position," Vohra said. 

With positive traction in our differentiated assets, the US business posted a revenue of USD 226 million, he stated. In South Africa, the drug maker recorded a solid growth of 21 per cent year on year in local currency terms, Vohra said. Emerging markets and Europe delivered a substantial revenue growth of 20 per cent year on year on the back of deep market focus strategy, he added. 

"Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front," Vohra said.